Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis

Erkka Valovirta, Aud Katrine Herland Berstad, Jacques de Blic, Albrecht Bufe, Peter Eng, Susanne Halken, Pedro Ojeda, Graham Roberts, Lene Tommerup, Eva-Maria Varga, Inger Winnergard, GAP investigators

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Allergic rhinoconjunctivitis is a risk factor for asthma development. Treating the underlying allergy may represent an attractive method of asthma prevention. No regulatory guidance exists in this area, and, to our knowledge, no clinical investigations meeting modern regulatory standards have been published.
OriginalsprogEngelsk
TidsskriftClinical Therapeutics
Vol/bind33
Udgave nummer10
Sider (fra-til)1537-46
Antal sider10
ISSN0149-2918
DOI
StatusUdgivet - 2011

Fingeraftryk

Pollen
Poaceae
Hypersensitivity

Citer dette

Valovirta, Erkka ; Berstad, Aud Katrine Herland ; de Blic, Jacques ; Bufe, Albrecht ; Eng, Peter ; Halken, Susanne ; Ojeda, Pedro ; Roberts, Graham ; Tommerup, Lene ; Varga, Eva-Maria ; Winnergard, Inger ; GAP investigators. / Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. I: Clinical Therapeutics. 2011 ; Bind 33, Nr. 10. s. 1537-46.
@article{03d3d0da1b7b48d58fb4d297ea2eadfa,
title = "Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis",
abstract = "Allergic rhinoconjunctivitis is a risk factor for asthma development. Treating the underlying allergy may represent an attractive method of asthma prevention. No regulatory guidance exists in this area, and, to our knowledge, no clinical investigations meeting modern regulatory standards have been published.",
author = "Erkka Valovirta and Berstad, {Aud Katrine Herland} and {de Blic}, Jacques and Albrecht Bufe and Peter Eng and Susanne Halken and Pedro Ojeda and Graham Roberts and Lene Tommerup and Eva-Maria Varga and Inger Winnergard and {GAP investigators}",
note = "Copyright {\circledC} 2011 Elsevier HS Journals, Inc. All rights reserved.",
year = "2011",
doi = "10.1016/j.clinthera.2011.09.013",
language = "English",
volume = "33",
pages = "1537--46",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Elsevier",
number = "10",

}

Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. / Valovirta, Erkka; Berstad, Aud Katrine Herland; de Blic, Jacques; Bufe, Albrecht; Eng, Peter; Halken, Susanne; Ojeda, Pedro; Roberts, Graham; Tommerup, Lene; Varga, Eva-Maria; Winnergard, Inger; GAP investigators.

I: Clinical Therapeutics, Bind 33, Nr. 10, 2011, s. 1537-46.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis

AU - Valovirta, Erkka

AU - Berstad, Aud Katrine Herland

AU - de Blic, Jacques

AU - Bufe, Albrecht

AU - Eng, Peter

AU - Halken, Susanne

AU - Ojeda, Pedro

AU - Roberts, Graham

AU - Tommerup, Lene

AU - Varga, Eva-Maria

AU - Winnergard, Inger

AU - GAP investigators

N1 - Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.

PY - 2011

Y1 - 2011

N2 - Allergic rhinoconjunctivitis is a risk factor for asthma development. Treating the underlying allergy may represent an attractive method of asthma prevention. No regulatory guidance exists in this area, and, to our knowledge, no clinical investigations meeting modern regulatory standards have been published.

AB - Allergic rhinoconjunctivitis is a risk factor for asthma development. Treating the underlying allergy may represent an attractive method of asthma prevention. No regulatory guidance exists in this area, and, to our knowledge, no clinical investigations meeting modern regulatory standards have been published.

U2 - 10.1016/j.clinthera.2011.09.013

DO - 10.1016/j.clinthera.2011.09.013

M3 - Journal article

VL - 33

SP - 1537

EP - 1546

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 10

ER -